Prenetics reports IM8 revenue up 288% in Q2 2026, raises full-year guidance

Prenetics Global Limited reported second quarter 2026 results on August 18, 2026, covering the period ended June 30, 2026. Total revenue was $46.5 million, up approximately 288% year over year, within the company's guidance of $46-48 million, while IM8 revenue was $45.0 million, up approximately 359% year over year, marking the sixth consecutive record quarter.¹

The company said July was IM8's strongest month ever, with $20.9 million in revenue, translating to a $251 million annualized revenue run-rate.¹ Prenetics defines that metric as an operating figure. Annualized Revenue Run-Rate is calculated by multiplying IM8 revenue recognized in the applicable month by twelve and includes revenue from both subscription and one-time purchases; it is not a financial measure under IFRS and the company cautions it may not indicate revenue in future periods.¹

CEO Danny Yeung said the quarter marked a turning point for the brand. He noted that twenty months after IM8's launch, the brand drove Prenetics to its sixth consecutive record quarter, with July as its biggest month, and said consolidated Adjusted Free Cash Flow turned positive for the first time and is expected to stay positive going forward.¹

The company raised its full-year total revenue guidance to $220 to $230 million and introduced 2027 IM8 revenue guidance of $400 million or more, which it said does not include any contribution from upcoming product launches.¹

Separately, the filing noted changes to Prenetics' portfolio. As part of a strategic repositioning toward its core consumer health and prevention businesses, the company divested or exited ACT Genomics, Europa, and Insighta, with the ACT Genomics sale to Delta Electronics, Inc. completing on October 1, 2025.¹ The Europa divestiture was completed in January 2026, and the disposal of Prenetics' remaining equity interest in Insighta was completed on February 13, 2026.¹